Novartis' Coartem Baby Receives WHO Prequalification for Malaria Treatment in Infants and a Positive CHMP Opinion for Itvisma

Novartis has achieved a significant milestone with WHO prequalification for its malaria treatment, Coartem Baby, for use in infants. This endorsement comes as the company continues to push the boundaries of treating malaria and ensuring access to life-saving treatments. Notably, Coartem Baby is the first malaria treatment aimed at newborns, offering a vital solution for vulnerable populations.

In a separate development, Novartis has received a positive CHMP opinion for Itvisma, their gene therapy aimed at treating spinal muscular atrophy (SMA). This marks an important step forward in the treatment landscape for a debilitating disease that affects thousands worldwide. The EU's regulatory backing is expected to pave the way for commercialization.

The twin announcements solidify Novartis' commitment to improving patient care, focusing on both treating diseases with existing solutions, like malaria, and pioneering innovative treatments for genetic disorders, like SMA.